Cardinal health™ nuclear & precision health solutions receives u.s. food and drug administration approval for new lymphoseek® pediatric indication

Dublin, ohio, june 10, 2021 /prnewswire/ -- cardinal health (nyse: cah) today announced that lymphoseek® (technetium tc 99m tilmanocept) injection – the first and only radiopharmaceutical agent specifically designed for targeted lymphatic mapping and guiding sentinel lymph node biopsies (slnb) – has been approved for pediatric use by the u.s. food and drug administration (fda). "this new indication opens the door for physicians, oncologists and nuclear medicine specialists to more accurately stage the spread of disease using lymphatic mapping in pediatric cancer patients," said tiffany olson, president of nuclear & precision health solutions at cardinal health.
CAH Ratings Summary
CAH Quant Ranking